| HAL |
Report |
Adjusted diluted EPS |
MISS |
pred ~$0.530 vs. cons $0.541 |
MEDIUM |
| HAL |
Report |
C&P revenue |
IN-LINE |
pred ~$3.150B vs. cons $3.162B |
MEDIUM |
| HAL |
Report |
D&E revenue |
IN-LINE |
pred ~$2.340B vs. cons $2.352B |
MEDIUM |
| HAL |
Guide |
C&P revenue (Q3 2026) |
LOWER |
guide ~$3.21B vs. cons $3.264B |
LOW |
| HAL |
Guide |
D&E revenue (Q3 2026) |
LOWER |
guide ~$2.32B vs. cons $2.352B |
LOW |
| HAL |
Guide |
FY 2026 CapEx |
UNKNOWN |
guide about $1.1B vs. cons UNVERIFIED |
MEDIUM |
| HAL |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| HAL |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — lower Q3 segment outlook should drive estimate cuts |
LOW |